HER2-Positive Breast Cancer Treatment — Personalised & Targeted
Medically reviewed by the CION Oncology Team · Last reviewed June 2026
HER2-positive breast cancer responds well to targeted treatment — but the right plan depends on your tumour's exact profile, stage, and your own goals. At CION, a tumor board of medical, surgical, and radiation oncologists reviews every case together in a single 45-minute consultation, so your treatment plan is never one doctor's opinion.
Tumor Board — Medical, surgical & radiation oncologists review your case together
96.9% 1-Year Survival — vs 85.4% national average* for breast cancer
17 Super-Specialists — 150+ years combined oncology experience at CION
HER2-positivity is not one-size-fits-all. The tumour's hormone-receptor status and stage determine which combination of treatments your team will recommend. Open each subtype to see what it means for your treatment.
Most common HER2+HER2-Positive / Hormone-Receptor Negative
This subtype tests positive for HER2 but negative for both oestrogen and progesterone receptors (ER−, PR−). It often grows and spreads quickly. Treatment focuses on targeted therapy combined with chemotherapy. Response to targeted therapy in this group can be remarkable, particularly when treatment starts early.
Triple-positiveTriple-Positive (HER2+, ER+, PR+)
Triple-positive breast cancer tests positive for HER2, oestrogen receptors, and progesterone receptors. This subtype typically grows more slowly than HER2+/hormone-receptor-negative cancers. Treatment combines targeted therapy, chemotherapy, and hormone-blocking therapy — the sequence matters greatly and is decided by your tumor board. New treatment for triple-positive breast cancer continues to evolve rapidly.
Earlier-stageEarly-Stage HER2-Positive Breast Cancer
When HER2-positive cancer is found at Stage I or II (tumour confined to the breast or nearby lymph nodes), the goal of treatment is cure. Treatment may include pre-surgery chemotherapy plus targeted therapy (neoadjuvant), surgery, post-surgery targeted therapy, and radiation. CION's 1-year breast cancer survival rate of 96.9% reflects outcomes predominantly in this early-stage group.
Advanced-stageMetastatic (Stage IV) HER2-Positive Breast Cancer
When HER2-positive cancer has spread beyond the breast and nearby lymph nodes to other organs, it is called metastatic or Stage IV. Treatment is focused on controlling the disease long-term, managing symptoms, and preserving quality of life. Multiple lines of targeted therapy and chemotherapy are available. Many patients with metastatic HER2-positive cancer live well for several years on treatment.
12+ Centres in Hyderabad · Pick yours
CION cancer care is closer than you think.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
Don't see your city? Call
18002028726
— we'll find your nearest CION partner centre.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
You Don't Have to Navigate This Alone
Our HER2 breast cancer specialists are ready to review your case, explain your options in plain language, and walk this journey with you from diagnosis to recovery.
How HER2-Positive Breast Cancer Is Diagnosed at CION
Accurate diagnosis is the foundation of the right treatment plan. Here is exactly what happens from your first appointment to a confirmed treatment plan — no unnecessary waiting.
Understanding your diagnosis — from biopsy, to confirmed HER2 status, to your personalised, tumor-board-led plan.
Step 01
Clinical Breast Examination
A surgical oncologist examines both breasts and the lymph nodes under your arms and near your collarbone. This takes about 15–20 minutes and is the starting point for deciding what imaging is needed.
Step 02
Imaging — Mammogram and / or Ultrasound
A mammogram maps the whole breast; an ultrasound gives detail on specific areas of concern. Together they help the team decide whether a biopsy is needed, and where exactly to take the sample from.
Step 03
Biopsy — Getting the Sample
A core needle biopsy removes a small piece of the lump under local anaesthesia. This is a same-day procedure. The tissue sample goes to our pathology lab, which will determine the cancer type and HER2 status.
Step 04
HER2 Testing — IHC Followed by FISH if Needed
The pathologist runs an IHC test. A score of 3+ is HER2-positive. A score of 2+ is borderline — CION always follows up with a FISH or CISH test to confirm, because a wrong HER2 score means the wrong treatment. You will never be put on a targeted therapy plan based on a borderline IHC alone.
Step 05
Hormone Receptor Testing (ER / PR)
The same biopsy sample is tested for oestrogen receptors (ER) and progesterone receptors (PR). This determines whether you have triple-positive breast cancer, which requires an additional hormone-blocking therapy component in the treatment plan.
Step 06
Staging Scans — PET-CT or CT + Bone Scan
Once HER2-positivity is confirmed, staging scans show whether the cancer has spread beyond the breast. A PET-CT gives whole-body information in one scan. CION has same-day digital PET-CT available at five locations in Hyderabad, with expert-reviewed reports.
Step 07
Tumor Board Meeting — Your Personalised Plan
With all results in hand, your case is presented to CION's multidisciplinary tumor board — medical oncologist, surgical oncologist, radiation oncologist, and pathologist together. Within 24–48 hours you receive a written treatment plan with a realistic timeline and a written cost estimate. No surprise bills.
Your Treatment Options
HER2 Breast Cancer Treatment Categories
HER2-positive breast cancer is treated with a combination of the categories below. Select a category to see how it works. Your tumor board selects and sequences these based on your stage, hormone-receptor status, age, and your own preferences. No drug or regimen names are listed here — those are clinical decisions made in your consultation, not on a webpage.
Targeted Therapy
Systemic treatment
This category of treatment works by blocking the HER2 protein specifically, disrupting the signal that tells cancer cells to grow and divide. Targeted therapy is the backbone of HER2-positive breast cancer treatment and is usually given alongside or after chemotherapy. It is administered via an intravenous infusion or as a tablet, depending on the agent your oncologist selects.
Chemotherapy
Systemic treatment
Anti-cancer medicines given in cycles — usually through an intravenous drip in a day-care setting. For HER2-positive breast cancer, chemotherapy is often given before surgery (neoadjuvant) to shrink the tumour, or after surgery (adjuvant) to reduce the risk of recurrence. It is almost always combined with targeted therapy for HER2-positive cases.
Surgery
Local treatment
Surgery removes the tumour from the breast. Breast-conserving surgery (lumpectomy) removes the tumour and a margin of healthy tissue; mastectomy removes the entire breast. The choice depends on tumour size relative to breast size, whether neoadjuvant treatment has shrunk the tumour, and your personal preference. Lymph node surgery (sentinel node biopsy or axillary clearance) is done at the same time to check spread.
Radiation Therapy
Local treatment
High-energy X-rays directed precisely at the breast and chest wall after surgery to destroy any remaining cancer cells. Radiation therapy after breast-conserving surgery significantly reduces the risk of local recurrence. Modern radiation techniques at CION minimise exposure to the heart and lungs — important for long-term health after breast cancer treatment.
Hormone-Blocking Therapy
Triple-positive only
Only relevant for triple-positive breast cancer (HER2+, ER+, PR+). Hormone-blocking therapy reduces the amount of oestrogen in the body or blocks its ability to stimulate cancer cell growth. It is typically given after chemotherapy and targeted therapy, and often continued for 5–10 years to reduce recurrence risk. Your oncologist will explain whether this applies to your specific case.
Allied Supportive Care
Whole-person care
Treatment does not end with anti-cancer therapy. CION's allied care team includes a clinical nutritionist (to maintain strength through treatment), a psycho-oncologist (to support mental wellbeing), and a physiotherapist (to manage lymphoedema and restore shoulder movement after surgery). You deserve care for the whole person — not just the tumour.
Treatment cost for HER2-positive breast cancer is indicative only and varies by stage, regimen length, and hospital centre. CION is empanelled with Aarogyasri, CGHS, ECHS, EHS, and major private insurers. EMI options available. Request a written cost estimate using the form below.
Outcomes at CION
CION Breast Cancer Survival — What the Numbers Show
Did you know?
CION's 1-year breast cancer survival rate is 96.9%, compared to the national average of 85.4%* — an 11.5 percentage-point difference. This reflects early diagnosis, accurate HER2 testing, and personalised tumor-board-led treatment for every patient. *1-year survival rate. Source: ICMR / NCRP national cancer registry data; CION internal clinical registry. Individual outcomes vary.
CION Cancer Clinics96.9%
National Average (India)85.4%
*1-year survival rate, breast cancer. CION figure: internal clinical registry. National figure: ICMR / NCRP data. Individual outcomes depend on stage, subtype, and treatment adherence. These figures are not a guarantee of any individual result.
Why Patients Choose CION
Why CION for Her2 Positive Breast Cancer Treatment?
Six reasons our patients tell us made the difference — each one backed by a specific system or practice, not a marketing claim.
01Confirmed HER2 Testing — No Guesswork on Your Most Critical Result
At CION, every IHC borderline (2+) result is followed up with a FISH or CISH test before any treatment plan is made. In India, a significant proportion of HER2 tests are done at laboratories without FISH follow-up capability — meaning some patients receive a wrong HER2 classification. A wrong result means the wrong treatment category entirely. We will not start your plan on a borderline IHC alone.
02Tumor Board for Every Patient — Not One Doctor's Opinion
HER2-positive breast cancer requires at least three specialists to get the plan right: a medical oncologist for systemic therapy, a surgical oncologist for the right operation, and a radiation oncologist for post-surgery treatment. At CION, these three review your case together before anyone recommends anything. This is not standard practice at most clinics — it is the standard at CION for every single patient, regardless of the stage or complexity of the case.
0317 Super-Specialists — 150+ Years of Combined Oncology Experience
CION has 17 super-specialist oncologists across medical, surgical, radiation, interventional, and haematology disciplines — with over 150 years of combined experience and 15,000+ patients treated. For breast cancer specifically, our medical oncologists are experienced in managing HER2-positive and triple-positive cases through all stages, including complex metastatic disease where sequencing of targeted therapy lines matters enormously.
04Transparent, Written Cost Estimates — No Surprise Bills Mid-Treatment
HER2-positive breast cancer treatment — particularly targeted therapy given over up to a year — can be expensive. CION gives you a written cost estimate before treatment begins, broken down by phase (surgery, chemotherapy cycles, targeted therapy duration, radiation). We verify your insurance or Aarogyasri / CGHS / ECHS / EHS coverage upfront. EMI options are available. You will never receive a bill category that was not discussed with you first.
05Woman-Led Organisation — A Safe Space for Breast Cancer Care
CION is a woman-headed organisation. For patients dealing with breast cancer — a diagnosis that touches identity, body image, fertility, and family — this matters. Our clinical team includes women oncologists who understand these concerns not just medically but personally. Discussions about breast-conserving surgery versus mastectomy, about fertility preservation before chemotherapy, and about post-treatment reconstruction happen in a space where you feel heard, not rushed.
0635+ Centres Across Telangana and AP — Care Close to Home
HER2-positive breast cancer treatment lasts many months — targeted therapy infusions, chemotherapy cycles, radiation sessions. Travelling long distances for every visit is exhausting. CION has 35+ centres across Telangana and Andhra Pradesh, with multiple centres in Hyderabad itself, so the bulk of your treatment happens close to home, close to your support system. Your care plan travels with you across CION centres — you are never starting from scratch with a new team.
Real Patients, Real Journeys
Hear From Patients Who Walked This Journey
Every patient's story is different. What is the same: you deserve to be heard, understood, and treated with a plan made for you — not a protocol copied from a textbook.
15,000+ patients chose CION. Hear from them directly.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
4.8★800+ Google reviews
50+video testimonials
15,000+patients treated
Successful Chemotherapy & Radiation Done by Dr. Owais Mohammed & Dr. Kirti Ranjan
Watch video →
Successful Chemotherapy Done by Dr. C Raghavendra Reddy
Watch video →
Surgery, Chemo & Radiation Done by Dr. Imaduddin, Dr. Vinay, Dr. Owais, Dr. Kirti
Watch video →
Successful Radical Thymectomy Done by Dr. Mohammed Imaduddin & Dr. Vinay Mamidala
Watch video →
Successful Surgery Done by Dr. Rajender Byshetty
Watch video →
Successful Chemo & Surgery Done by Dr. Imad, Dr. Vinay, Dr. Owais & Dr. Raghavendra
Watch video →
Successful Chemo & Surgery Done by Dr. Imad, Dr. Vinay, Dr. Owais & Dr. Raghavendra
Watch video →
Successful Chemo & Radiation Done by Dr. Owais Mohammed & Dr. Kirti Ranjan Mohanty
Watch video →
Successful Breast Cancer Surgery Done by Dr. Imaduddin Mohammed & Dr. Vinay Mamidala
Watch video →
Successful Chemotherapy Done by Dr. Bharati Devi Gorantla
Watch video →
Successful Chemo & Surgery Done by Dr. Owais Mohammed & Dr. Imaduddin Mohammed
Watch video →
Successful Chemotherapy Done by Dr. Gundu Naresh
Watch video →
Successful Bone Marrow Transplantation - Neuroblastoma
Watch video →
Successful Surgery & Chemo - Carcinoma of Caecum
Watch video →
Successful Oral chemotherapy & mastectomy surgery
Watch video →
Successful Oral chemotherapy & mastectomy surgery
Watch video →
Successful Chemotherapy
Watch video →
Successful Surgery by Dr. Mohammed Imaduddin
Watch video →
Successful Bone Marrow Transplantation
Watch video →
Successful Oral chemotherapy & mastectomy surgery
Watch video →
Successful Oral chemotherapy & mastectomy surgery
Watch video →
Successful Chemotherapy
Watch video →
Successful Buccal Mucosa Surgery
Watch video →
Successful Complex Surgery Mandibulectomy Reconstruction
HER2 Breast Cancer Treatment — Frequently Asked Questions
What is HER2-positive breast cancer and how is it different from other types?
HER2-positive breast cancer has extra copies of the HER2 gene, which makes cancer cells grow faster than other types. It is found in roughly 1 in 5 breast cancer cases. The good news is that HER2-positive tumours respond well to targeted therapy — a category of treatment designed to block the HER2 protein specifically. At CION, every patient's HER2 status is confirmed by both IHC and FISH testing before we plan treatment, so you never receive a plan based on incomplete information.
What treatment options are available for HER2-positive breast cancer?
HER2-positive breast cancer is treated with a combination of approaches chosen for your specific situation. The main categories are targeted therapy (medicines that block the HER2 protein), chemotherapy, surgery (breast-conserving or mastectomy depending on tumour size and your preference), radiation therapy, and — when the cancer is also hormone-receptor positive — hormone-blocking therapy. Your CION tumor board — medical, surgical, and radiation oncologists together — will review your case and recommend the combination that gives you the best outcome with the fewest side effects.
What does 'triple-positive' breast cancer mean and how is it treated?
Triple-positive breast cancer means the tumour tests positive for HER2, oestrogen receptors (ER+), and progesterone receptors (PR+). This subtype often grows more slowly than HER2-positive/hormone-negative cancers, and it can be treated with targeted therapy, hormone-blocking therapy, and chemotherapy — sometimes together, sometimes in sequence. Our tumor board reviews each triple-positive case individually, because the right sequencing of treatments matters as much as the treatments themselves.
How long does HER2-positive breast cancer treatment take?
The total duration depends on the stage and the combination of treatments recommended. Targeted therapy for HER2-positive breast cancer is often given for up to a year. Chemotherapy cycles typically run over several months. Surgery and radiation each add to the overall timeline. At CION, your care team will map out the full journey — with realistic timelines — during your first 45-minute consultation, so you can plan your work and family life around treatment without surprises.
What is the cost of HER2-positive breast cancer treatment in Hyderabad?
The indicative cost of HER2-positive breast cancer treatment in Hyderabad ranges widely depending on stage, the combination of treatments needed, and duration of targeted therapy. CION is empanelled with Aarogyasri, CGHS, ECHS, EHS, and all major insurance providers, and our team will verify your coverage before your first appointment. We also offer EMI options. To get a written cost estimate specific to your case — with no obligation — call us or use the form on this page.
Can HER2-positive breast cancer be detected early, and does early detection improve outcomes?
Yes — HER2-positive breast cancer detected at an early stage responds very well to treatment. CION's 1-year survival rate for breast cancer is 96.9%, compared to the national average of 85.4%* — a difference that reflects early, accurate diagnosis and personalised tumor-board-led care. If you have a breast lump, nipple change, or persistent pain, do not wait. A clinical examination and biopsy confirm the diagnosis and HER2 status within days at CION. *1-year survival rate. Source: ICMR / NCRP data; CION internal clinical registry.
The information on this page is for general awareness only and does not constitute medical advice. HER2-positive breast cancer treatment must be planned by a qualified oncologist based on individual diagnosis, staging, and test results. All survival figures are 1-year rates (CION internal registry; ICMR/NCRP national data) and do not represent a guarantee of any individual outcome. Cost figures are indicative only and will vary based on treatment protocol and duration. CION Cancer Clinics is a division of CIPHER ONCOLOGY.
CION Ameerpet
